Holen Sie sich die Stockscreener-App
20.35
1.45%
0.29
Handel nachbörslich:
20.36
0.010
+0.05%
Schlusskurs vom Vortag:
$20.06
Offen:
$19.86
24-Stunden-Volumen:
2.37M
Relative Volume:
1.19
Marktkapitalisierung:
$3.43B
Einnahmen:
$890.53M
Nettoeinkommen (Verlust:
$30.57M
KGV:
113.06
EPS:
0.18
Netto-Cashflow:
$80.53M
1W Leistung:
-5.52%
1M Leistung:
-13.81%
6M Leistung:
+36.94%
1J Leistung:
+35.76%
1-Tages-Spanne:
$19.72
$20.47
1-Wochen-Bereich:
$19.69
$21.71
52-Wochen-Spanne:
$13.40
$26.65
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Firmenname
Acadia Pharmaceuticals Inc
Sektor
Branche
Telefon
858-558-2871
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Vergleichen Sie ACAD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
20.35 | 3.38B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-21 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2025-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-03-12 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-12 | Bestätigt | Needham | Buy |
| 2024-01-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-01-24 | Hochstufung | Needham | Hold → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-10-10 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-11-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-08-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-21 | Herabstufung | Jefferies | Buy → Underperform |
| 2022-06-16 | Hochstufung | Jefferies | Hold → Buy |
| 2022-03-16 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-21 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-06-10 | Eingeleitet | Berenberg | Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-04-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-04-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2021-03-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-11-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-07 | Hochstufung | Stifel | Hold → Buy |
| 2020-04-16 | Eingeleitet | Jefferies | Buy |
| 2020-03-31 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-09-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Bestätigt | Needham | Buy |
| 2018-12-10 | Eingeleitet | Canaccord Genuity | Hold |
| 2018-09-21 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-08-06 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
Is ACADIA Pharmaceuticals Inc. stock trading near support levelsTrade Analysis Report & Expert-Curated Trade Recommendations - newser.com
How to track smart money flows in ACADIA Pharmaceuticals Inc.2025 Trading Volume Trends & Entry Point Confirmation Signals - newser.com
Real time alert setup for ACADIA Pharmaceuticals Inc. performancePortfolio Growth Summary & Real-Time Market Trend Scan - newser.com
Ranking ACADIA Pharmaceuticals Inc. among high performing stocks via toolsRisk Management & Advanced Technical Signal Analysis - newser.com
How sentiment analysis helps forecast ACADIA Pharmaceuticals Inc.Portfolio Value Report & Weekly Hot Stock Watchlists - newser.com
Applying Elliott Wave Theory to ACADIA Pharmaceuticals Inc.Weekly Loss Report & Risk Adjusted Swing Trade Ideas - newser.com
Why ACADIA Pharmaceuticals Inc. stock could be next big winnerTrade Volume Report & Safe Entry Zone Identification - newser.com
Leerink Partnrs Issues Optimistic Outlook for ACAD Earnings - MarketBeat
Heatmap analysis for ACADIA Pharmaceuticals Inc. and competitors2025 Pullback Review & Weekly Market Pulse Alerts - newser.com
How high can ACADIA Pharmaceuticals Inc. stock go2025 Institutional Moves & Free Weekly Chart Analysis and Trade Guides - newser.com
Detecting support and resistance levels for ACADIA Pharmaceuticals Inc.2025 Macro Impact & Verified Momentum Watchlists - newser.com
Using Bollinger Bands to evaluate ACADIA Pharmaceuticals Inc.July 2025 Momentum & AI Enhanced Execution Alerts - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc.ACAD - PR Newswire
Q3 EPS Estimate for ACADIA Pharmaceuticals Cut by Analyst - MarketBeat
RBC Cuts Price Target on ACADIA Pharmaceuticals to $34 From $40, Keeps Outperform Rating - MarketScreener
Acadia Healthcare Company, Inc. Announces Chief Financial Officer Changes, Effective October 27, 2025 - MarketScreener
What drives ACADIA Pharmaceuticals Inc stock priceHead and Shoulders Patterns & Double Digit Capital Growth - earlytimes.in
How to interpret RSI for ACADIA Pharmaceuticals Inc. stockWeekly Risk Summary & Reliable Intraday Trade Alerts - newser.com
Real time social sentiment graph for ACADIA Pharmaceuticals Inc.Volume Spike & Weekly Chart Analysis and Trade Guides - newser.com
Detecting price anomalies in ACADIA Pharmaceuticals Inc. with AI2025 Price Action Summary & Weekly Chart Analysis and Trade Guides - newser.com
ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish (ACAD) - Seeking Alpha
Is ACADIA Pharmaceuticals Inc. stock attractive after correctionRate Hike & Weekly High Conviction Ideas - newser.com
Wealth Enhancement Advisory Services LLC Makes New $511,000 Investment in ACADIA Pharmaceuticals Inc. $ACAD - Defense World
Intraday pattern recognizer results for ACADIA Pharmaceuticals Inc.2025 Trading Recap & Technical Entry and Exit Alerts - newser.com
Using R and stats models for ACADIA Pharmaceuticals Inc. forecastingWall Street Watch & Reliable Intraday Trade Alerts - newser.com
News impact scoring models applied to ACADIA Pharmaceuticals Inc.2025 Sector Review & Stock Portfolio Risk Control - newser.com
What machine learning models say about ACADIA Pharmaceuticals Inc.Swing Trade & Expert Verified Stock Movement Alerts - newser.com
Will ACADIA Pharmaceuticals Inc. rebound enough to break even2025 Bull vs Bear & Weekly Breakout Watchlists - newser.com
Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study - MSN
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
ACADIA Pharmaceuticals Inc. Securities Lawsuit Investigation - Claim Depot
Using flow based indicators on ACADIA Pharmaceuticals Inc.Weekly Loss Report & High Conviction Trade Alerts - newser.com
A Look at Acadia Pharmaceuticals’s Valuation After Setback in Phase 3 Prader-Willi Trial - Sahm
Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders - BioSpace
Published on: 2025-10-03 03:21:29 - newser.com
Acadia to present pipeline updates at Parkinson’s congress By Investing.com - Investing.com Nigeria
Acadia, e-therapeutics unveil rebrands to better represent their drugmaking missions - Fierce Pharma
Acadia to present pipeline updates at Parkinson’s congress - Investing.com
Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):